XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
Z
Z

Zimmer


Actualités

Zimmer Biomet Holdings Inc reports results for the quarter ended in June - Earnings Summary

Zimmer Biomet Holdings Inc reports results for the quarter ended in June - Earnings Summary Zimmer Biomet Holdings Inc ZBH.N reported quarterly adjusted earnings of $2.01​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $1.82. The mean expectation of twenty seven analysts for the quarter was for earnings of $1.99 per share.
Z

Zimmer Biomet beats profit estimates on strong demand for medical devices

Zimmer Biomet beats profit estimates on strong demand for medical devices Aug 7 (Reuters) - Zimmer Biomet Holdings ZBH.N beat Wall Street estimates for second-quarter profit on Wednesday, driven by robust demand for its devices used in joint reconstruction procedures. Medical device makers have boosted investor expectations in the recent quarters as more people, especially older Americans, opt for non-urgent surgeries such as hip and knee replacements.
S
Z

Zimmer Biomet Signs Definitive Agreement To Acquire OrthoGrid Systems, Inc.

BRIEF-Zimmer Biomet Signs Definitive Agreement To Acquire OrthoGrid Systems, Inc. Aug 7 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET SIGNS DEFINITIVE AGREEMENT TO ACQUIRE ORTHOGRID SYSTEMS, INC. Source text for Eikon: ID:nPn2rpgcxa Further company coverage: ZBH.N
Z

Shopify soars as AI focus powers quarterly beat, bullish forecast

UPDATE 4-Shopify soars as AI focus powers quarterly beat, bullish forecast Adds details from call in paragraphs 4, 7, 12, analyst comment in paragraph 4, updates share movement in paragraph 1 Aug 7 (Reuters) - Shopify SHOP.TO beat analysts' estimates for second-quarter results and forecast upbeat sales growth on Wednesday as its AI-enabled tools attracted more merchants to its e-commerce services, sending its shares up more than 20%.
Z

Zimmer Biomet Q2 Adjusted EPS USD 2.01 Vs. IBES Estimate USD 1.99

BRIEF-Zimmer Biomet Q2 Adjusted EPS USD 2.01 Vs. IBES Estimate USD 1.99 Aug 07 (Reuters) - Zimmer Biomet Q2 net income USD 242.8 million. Q2 EPS USD 1.18 Q2 sales USD 1,942 million vs. IBES estimate USD 1,941 million outlook FY adjusted EPS USD 8-8.15
Z

BOJ eases market migraine, Super Micro aches

MORNING BID AMERICAS-BOJ eases market migraine, Super Micro aches A look at the day ahead in U.S. and global markets from Mike Dolan In an extraordinary round trip over the past week, world markets have rebounded sharply from days of turbulence - thanks in part to Bank of Japan almost apologising on Wednesday for its role in the ruckus - and traders now try to figure out what's next.
M
N
U
J
U
U
U
F
U
Z
A

U.S. STOCKS Synchrony Financial, Crypto Stocks, Industrial REITs

BUZZ-U.S. STOCKS ON THE MOVE-Synchrony Financial, Crypto Stocks, Industrial REITs Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq tumbled more than 2% to a two-week low on Wednesday, pulled down as megacap chip and tech stocks fell on the prospect of tighter China-focused U.S.
A
C
E
I
M
N
X
U
U
Z

Some medical device makers rise, while others tip lower after J&J results

BUZZ-Some medical device makers rise, while others tip lower after J&J results ** Some medical device manufacturers rise after Johnson & Johnson's JNJ.N results, while others fall ** Zimmer Biomet ZBH.N rise 2.9% to $110.58, Medtronic MDT.N gain 2.45% to $80.01, Abbott ABT.N rise 2.10% to $104.90, Stryker SYK.N up 1.04% at $336.90 ** Shares of Intu
A
C
S
Z

Australia's Osteopore surges on exclusive distribution agreement

BUZZ-Australia's Osteopore surges on exclusive distribution agreement ** Shares of medical technology firm Osteopore OSX.AX rise as much as 35.7% to A$0.076 ** Stock hits highest level, and posts its biggest intraday pct gain since June 6 ** Co says it signed an exclusive distribution agreement with a unit of Singapore-based Zimmer Biomet ZBH.N **
Z

Zimmer Biomet Holdings On June 28, Got Into A New Five-Year Revolving Credit Agreement & New 364-Day Revolving Credit Agreement

BRIEF-Zimmer Biomet Holdings On June 28, Got Into A New Five-Year Revolving Credit Agreement & New 364-Day Revolving Credit Agreement July 1 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET HOLDINGS: ON JUNE 28, GOT INTO A NEW FIVE-YEAR REVOLVING CREDIT AGREEMENT & NEW 364-DAY REVOLVING CREDIT AGREEMENT ZIMMER BIOMET HOLDINGS INC: FIVE-
Z

U.S. AT&T, ATI, California Resources

U.S. RESEARCH ROUNDUP-AT&T, ATI, California Resources July 1 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including AT&T, ATI and California Resources, on Monday. HIGHLIGHTS * AT&T Inc T.N : JP Morgan adds stock to its U.S. analyst focus list * ATI Inc ATI.N : JP Morgan removes stock from its U.S.
A
I
N
W
H
Z
T
U

RevelAi Health And Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement To Advance Value-Based Care And Health Equity Through Powered Technology

BRIEF-RevelAi Health And Zimmer Biomet Announce Exclusive Multi-Year Co-Marketing Agreement To Advance Value-Based Care And Health Equity Through AI-Powered Technology June 12 (Reuters) - Zimmer Biomet Holdings Inc ZBH.N : REVELAI HEALTH AND ZIMMER BIOMET ANNOUNCE EXCLUSIVE MULTI-YEAR CO-MARKETING AGREEMENT TO ADVANCE VALUE-BASED CARE AND HEALTH EQ
Z

Zimmer Biomet Holdings Inc Sees Mid-Single-Digit Percentage Constant Currency Consolidated Revenue Compound Annual Growth Rate For 2024 Through 2027

BRIEF-Zimmer Biomet Holdings Inc Sees Mid-Single-Digit Percentage Constant Currency Consolidated Revenue Compound Annual Growth Rate For 2024 Through 2027 Zimmer Biomet Holdings Inc ZBH.N : ZIMMER BIOMET HOLDINGS INC: SEES MID-SINGLE-DIGIT PERCENTAGE CONSTANT CURRENCY CONSOLIDATED REVENUE COMPOUND ANNUAL GROWTH RATE FOR 2024 THROUGH 2027 ZIMMER BIO
Z



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques